| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 374.466 | 399.853 | 595.063 | 826.599 | 832.274 | 935.986 | 1.034.626 | 1.207.776 | 1.301.053 | 1.271.014 |
| Total Income - EUR | 374.468 | 399.855 | 597.513 | 827.334 | 834.435 | 941.988 | 1.037.869 | 1.221.627 | 1.329.155 | 1.294.070 |
| Total Expenses - EUR | 383.345 | 386.315 | 613.895 | 792.498 | 788.428 | 888.687 | 971.348 | 1.167.678 | 1.257.667 | 1.229.279 |
| Gross Profit/Loss - EUR | -8.877 | 13.540 | -16.383 | 34.836 | 46.006 | 53.301 | 66.521 | 53.949 | 71.487 | 64.791 |
| Net Profit/Loss - EUR | -8.877 | 11.360 | -21.983 | 26.568 | 37.662 | 44.559 | 56.143 | 46.754 | 61.422 | 56.190 |
| Employees | 10 | 11 | 15 | 18 | 16 | 17 | 18 | 16 | 14 | 10 |
Check the financial reports for the company - Adamapharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 25.911 | 18.903 | 11.778 | 4.685 |
| Current Assets | 146.396 | 140.966 | 221.908 | 276.569 | 254.514 | 337.651 | 405.165 | 488.766 | 493.086 | 548.786 |
| Inventories | 93.164 | 91.217 | 143.879 | 161.225 | 149.726 | 201.158 | 239.979 | 286.464 | 303.593 | 357.248 |
| Receivables | 44.524 | 23.450 | 64.689 | 96.195 | 73.375 | 98.709 | 113.826 | 137.033 | 141.343 | 83.370 |
| Cash | 8.708 | 26.299 | 13.340 | 19.149 | 31.413 | 37.785 | 51.360 | 65.270 | 48.149 | 108.167 |
| Shareholders Funds | 18.533 | 29.703 | 7.217 | 33.653 | 49.590 | 72.535 | 94.725 | 101.218 | 121.900 | 117.099 |
| Social Capital | 56 | 56 | 55 | 54 | 53 | 52 | 51 | 51 | 51 | 50 |
| Debts | 127.863 | 111.263 | 214.691 | 242.917 | 204.925 | 265.116 | 336.351 | 406.451 | 382.964 | 436.372 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Adamapharm S.r.l.